New cell and gene therapies “have the potential to revolutionize treatment” for a number of diseases, but that doesn’t come without a hefty price tag, the authors of a recent Health Affairs blog post write.
The therapies themselves, however, could offer “substantial savings” as they cure conditions that might “otherwise be expensive to treat.”
“For example, the lifetime costs of hemophilia A can exceed $20 million,” the authors write. “A successful new therapy has the potential to reduce many of these costs.”
To read the full blog post, click here.